Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (21-30 of 141) with videos related to

Pageof 15
Sort By:
The Urologic Clinics of North America|July 1, 2020
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell CarcinomaKyrollis Attalla, Stanley Weng, Martin H Voss, et al.
Cancer Discovery|September 19, 2019
Tumor Microenvironment Dynamics in Clear-Cell Renal Cell CarcinomaLynda Vuong, Ritesh R Kotecha, Martin H Voss, et al.
Hematology/Oncology Clinics of North America|May 17, 2011
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumorsMartin H Voss, Darren R Feldman, George J Bosl, et al.
Journal for Immunotherapy of Cancer|December 25, 2021
In silico modeling of combination systemic therapy for advanced renal cell carcinomaRitesh R Kotecha, Dennis J Hsu, Chung-Han Lee, et al.
British Journal of Cancer|June 27, 2020
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse eventsViktor Grünwald, Martin H Voss, Brian I Rini, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2012
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experienceMartin H Voss, Matthew A Lunning, Jocelyn C Maragulia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2021
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell CarcinomaRitesh R Kotecha, Ronan Flippot, Taylor Nortman, et al.
Clinical Genitourinary Cancer|July 16, 2014
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasisDiogo A Bastos, Ana M Molina, Vaios Hatzoglou, et al.
British Journal of Cancer|February 25, 2016
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinomaMartin H Voss, David Chen, Mahtab Marker, et al.
Future Oncology (London, England)|October 26, 2023
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinomaToni K Choueiri, Thomas Powles, Martin H Voss, et al.
Pageof 15

Showing results (21-30 of 141) with videos related to

Sort By:
Pageof 15
The Urologic Clinics of North America|July 1, 2020
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell CarcinomaKyrollis Attalla, Stanley Weng, Martin H Voss, et al.
Cancer Discovery|September 19, 2019
Tumor Microenvironment Dynamics in Clear-Cell Renal Cell CarcinomaLynda Vuong, Ritesh R Kotecha, Martin H Voss, et al.
Hematology/Oncology Clinics of North America|May 17, 2011
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumorsMartin H Voss, Darren R Feldman, George J Bosl, et al.
Journal for Immunotherapy of Cancer|December 25, 2021
In silico modeling of combination systemic therapy for advanced renal cell carcinomaRitesh R Kotecha, Dennis J Hsu, Chung-Han Lee, et al.
British Journal of Cancer|June 27, 2020
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse eventsViktor Grünwald, Martin H Voss, Brian I Rini, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2012
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experienceMartin H Voss, Matthew A Lunning, Jocelyn C Maragulia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2021
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell CarcinomaRitesh R Kotecha, Ronan Flippot, Taylor Nortman, et al.
Clinical Genitourinary Cancer|July 16, 2014
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasisDiogo A Bastos, Ana M Molina, Vaios Hatzoglou, et al.
British Journal of Cancer|February 25, 2016
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinomaMartin H Voss, David Chen, Mahtab Marker, et al.
Future Oncology (London, England)|October 26, 2023
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinomaToni K Choueiri, Thomas Powles, Martin H Voss, et al.
Pageof 15